A brand-new look!
We are excited to announce that Julius Clinical has a brand-new look and website as part of the ongoing evolution of our company’s brand.
Why?
Ever since its foundation in 2008, Julius Clinical has been based on a unique triangle of scientific rigor, operational excellence, and strong site networks. While this remains the core of our company, we have grown and evolved over the past 15 years, and we came to realize that we have become so much more. This is symbolized by the hexagon in our new logo, that surrounds the well-known triangle.
When. Trials. Matter.
Over the past months, we analysed our organization’s values and created a brand identity that reflects those values. Our pay-off: “When.Trials.Matter.” reflects our endless commitment to supporting global clinical drug trials that will have a major impact on medicine and make a real difference to lives all around the world.
A big thank you
The rebranding has been a major process, involving many people from both inside and outside the organisation. We would like to express our appreciation to everyone who has contributed to this process. We could not have done it without you!
What’s next?
Over the coming weeks, the changes will become more and more visible. But for now, we would like to invite you to explore our brand-new website.
Related news
Cardiovascular risk in elderly with obesity and liver fibrosis: Benefits of statins
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
First official meeting of the Julius Clinical Dementia Scientific Advisory Board
At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clin...
Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs)...